Literature DB >> 12221591

Muscarinic agonist properties involved in the hypotensive and vasorelaxant responses of rotundifolone in rats.

D N Guedes1, D F Silva, J M Barbosa-Filho, I A Medeiros.   

Abstract

The acute cardiovascular effects of rotundifolone (ROT), the major constituent (63.5 %) of the essential oil of Mentha x villosa (OEMV), were tested in rats by using a combined (in vivo and in vitro) approach. ROT (1, 5, 10, 20 and 30 mg kg(-1) i. v.) induced a significant and dose-dependent hypotension and bradycardia in non-anaesthetized normotensive rats. The hypotensive effect was significantly attenuated by pre-treatment of the rats with atropine (2 mg kg(-1) i. v.) or L-NAME (20 mg kg(-1) i. v.). Furthermore, the bradycardic effect was abolished by atropine. In isolated rat atrial preparations, ROT (10, 100, 300 and 500 microg ml(-1)) produced concentration-related negative inotropic and chronotropic effects. In isolated intact aortic rings, increasing concentractions of ROT (0.3, 1, 10, 100, 300 and 500 microg ml(-1)) were able to antagonize the contractile effect of phenylephrine (1 microM) (IC50 = 184 +/- 6 microg ml(-1)). The smooth muscle-relaxant activity of ROT was inhibited by either removal of vascular endothelium, atropine (1 microM), L-NAME (100 and 300 microM) or indomethacin (10 microM) (IC50 values = 235 +/- 7, 247 +/- 8, 387 +/- 21, 723 +/- 75 and 573 +/- 38 microg ml(-1), respectively). These results suggest that rotundifolone markedly lowers arterial pressure and heart rate in non-anaesthetized animals. The hypotensive action of rotundifolone can be a consequence of a decrease in heart rate and peripheral vascular resistance, probably due to a non-selective muscarinic receptor stimulation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12221591     DOI: 10.1055/s-2002-33795

Source DB:  PubMed          Journal:  Planta Med        ISSN: 0032-0943            Impact factor:   3.352


  7 in total

Review 1.  Aromatherapy in the management of psychiatric disorders: clinical and neuropharmacological perspectives.

Authors:  Nicolette Perry; Elaine Perry
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 2.  Was Hawan Designed to Fight Anxiety-Scientific Evidences?

Authors:  R K Romana; A Sharma; V Gupta; R Kaur; S Kumar; P Bansal
Journal:  J Relig Health       Date:  2020-02

Review 3.  Vasodilator compounds derived from plants and their mechanisms of action.

Authors:  Francisco J Luna-Vázquez; César Ibarra-Alvarado; Alejandra Rojas-Molina; Isela Rojas-Molina; Miguel Angel Zavala-Sánchez
Journal:  Molecules       Date:  2013-05-17       Impact factor: 4.411

4.  Structural relationships and vasorelaxant activity of monoterpenes.

Authors:  Tamires Cardoso Lima; Marcelo Mendonça Mota; José Maria Barbosa-Filho; Márcio Roberto Viana Dos Santos; Damião Pergentino De Sousa
Journal:  Daru       Date:  2012-09-03       Impact factor: 3.117

Review 5.  Is There Any Scientific Basis of Hawan to be used in Epilepsy-Prevention/Cure?

Authors:  Parveen Bansal; Ramandeep Kaur; Vikas Gupta; Sanjiv Kumar; RamanPreet Kaur
Journal:  J Epilepsy Res       Date:  2015-12-31

6.  TRPM8 Channel Activation Induced by Monoterpenoid Rotundifolone Underlies Mesenteric Artery Relaxation.

Authors:  Darizy Flavia Silva; Monica Moura de Almeida; Cinthia Guedes Chaves; Ana Letícia Braz; Maria Aparecida Gomes; Leidiane Pinho-da-Silva; Jorge Luiz Pesquero; Viviane Aguiar Andrade; Maria de Fátima Leite; José George Ferreira de Albuquerque; Islania Giselia Albuquerque Araujo; Xirley Pereira Nunes; José Maria Barbosa-Filho; Jader dos Santos Cruz; Nadja de Azevedo Correia; Isac Almeida de Medeiros
Journal:  PLoS One       Date:  2015-11-23       Impact factor: 3.240

Review 7.  Secondary Metabolites of Plants as Modulators of Endothelium Functions.

Authors:  Anna Bartáková; Marie Nováková
Journal:  Int J Mol Sci       Date:  2021-03-03       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.